About Us

We help early-stage and mid-sized biotech companies build market access the right way — early, strategically, and with confidence.

For emerging biopharma organizations, market access decisions made today shape commercial success for years to come. We partner with early-stage biotech teams to translate clinical innovation into clear, credible access strategies that resonate with payers, providers, and investors—without overbuilding or overcomplicating.

Our experience spans Primary Care (Respiratory & Immunology), Rare Diseases, Oncology (Hematology, IO, Lung, Breast), and cell and gene therapy, with a deep understanding of how payers and providers evaluate evidence, price risk, and reimbursement pathways long before launch. We help teams anticipate access hurdles early, pressure-test assumptions, and make smart, capital-efficient choices as programs move from Phase 2 through Phase 3 and into commercialization.

We specialize in:

U.S. payer and provider access strategy
Pricing, contracting, and gross-to-net optimization
Launch readiness and early market shaping
Account strategy for payers, IDNs, community oncology, and specialty networks
Value proposition development and payer-facing evidence strategy
Field enablement and access team build-out
Market Access operations enablement
Access Analytics

What sets us apart is our operator mindset. We have built and led market access organizations, launched therapies in complex reimbursement environments, and worked cross-functionally with Clinical, Medical, Regulatory, Finance, and Commercial teams. This allows us to give early-stage leaders practical guidance that aligns science, strategy, and execution — while avoiding costly rework later.

Our approach is pragmatic, collaborative, and tailored. We meet teams where they are; whether preparing for an investor meeting, an end-of-Phase-2 interaction, a partnership discussion, or a first U.S. launch — and help them make informed decisions that reduce risk and accelerate patient access.

At our core, we believe strong market access strategy is a growth enabler — not a launch-day function. Our role is to help emerging biotech companies build that capability thoughtfully, efficiently, and with the future in mind.